Bipolar disorder comes in many distinct forms and genetic differences cause people to respond differently to lithium, paving ...

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...

Bipolar disorder is genetic, but research suggests that there is both a genetic component and environmental one that contribute to its development.

While borderline personality disorder and bipolar disorder share common symptoms like reckless behavior, there are a few key ...

Emerging technologies, such as functional near-infrared spectroscopy, offer in-office real-time monitoring for potential ...

Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 ...

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline ...

A groundbreaking Genomic Press interview explores how Dr. Martin Alda transformed worldwide understanding of bipolar disorder ...

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat ...

An overview of how genetics associated with schizophrenia and bipolar can influence how cells communicate, ultimately ...

By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.

US researchers have revealed for the first time how neurons malfunction in the brains of patients with Cho Hyun disease (schizophrenia) and bipolar disorder using lab-grown brain organoids ...